Form 20-F

Cloopen Group ($RAASY) files 2025 annual report on Form 20-F with SEC, disclosing audited financials for China's cloud communications platform.

YXT.com filed its 2025 annual report with the SEC, reporting full-year results as the AI-enabled enterprise productivity provider seeks expanded market recognition.

17 Education & Technology Group ($YQ) files 2025 Form 20-F with SEC, disclosing annual audited financials as Chinese edtech faces ongoing regulatory pressures.

Xunlei Limited ($XNET) filed its 2025 Form 20-F annual report with the SEC on April 28, 2026, providing comprehensive financial disclosures for the distributed cloud services provider.

Trident Digital Tech files 2025 annual report with SEC, advancing blockchain-based Tridentity identity solution targeting African growth markets.

Qfin Holdings filed its 2025 Form 20-F annual report and raised its semi-annual dividend, signaling confidence in its AI-powered credit platform performance.

FEMSA files 2025 annual report with SEC, disclosing operations across 18 countries with 392,000+ employees spanning retail, convenience stores, and beverage bottling.

Jianpu Technology files 2025 annual report with SEC, disclosing financial details for its Rong360 fintech platform operating in China.

Hesai Group filed 2025 annual report with SEC, reporting Q4 revenues of $143.1M, record 631,095 lidar shipments, and $21.9M net income.

CMB.TECH NV files 2025 annual report and Form 20-F, announces shareholder meetings May 21, 2026. Maritime operator manages ~250 vessels across dry bulk, tankers, containers.

TOP Ships Inc. filed its 2025 Form 20-F annual report, offering investors comprehensive tanker sector performance data and financial disclosures.

Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.

Alvotech files 2025 annual report with SEC, reporting five marketed biosimilars and nine additional candidates in development across therapeutic areas.

Alvotech files 2025 Annual Report on Form 20-F with SEC, providing comprehensive financial disclosures to U.S. investors via SEC Edgar and company website.

Alvotech files 2025 annual report showing five approved biosimilars and nine pipeline candidates across multiple therapeutic areas, positioning the company amid rapid biosimilar market growth.

Alvotech files 2025 Form 20-F, revealing operations across six continents as the Icelandic biosimilar developer pursues international market expansion.

Alvotech files 2025 annual SEC report with five marketed biosimilars and nine pipeline candidates supported by global partnerships.

Costamare Bulkers files 2025 annual report, operating 31 dry bulk vessels with 2.8M DWT capacity amid volatile shipping markets.

Aegon published its 2025 Integrated Annual Report, reporting EUR 375M net result in H2 2025 while announcing executive leadership changes across its operations.

Marex Group ($MRX) files 2025 Form 20-F annual report with SEC, disclosing comprehensive financial performance and operational metrics to shareholders.